Amgen - AstraZeneca's Asthma Candidate Under Priority Review With FDA - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

The FDA has accepted for review Amgen Inc's AMGN marketing application seeking approval for tezepelumab to treat asthma.
Amgen is developing Tezepelumab in collaboration with AstraZeneca plc AZN.
Under priority review status, the agency's goal date for a decision by the FDA is during Q1 of 2022.
Tezepelumab was granted an FDA Breakthrough Therapy Designation for patients with severe asthma without an eosinophilic phenotype in September 2018.
Tezepelumab is a human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults.
Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine, and initiates an overreactive immune response to airway inflammation.
Price Action: AMGN stock closed at $243.22 on Wednesday, while AZN shares are down 0.9% at $59.21 during the premarket session on the last check Thursday.